PRESS RELEASE published on 05/14/2025 at 15:00, 1 year 1 month ago Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates Jaguar Health, Inc. to file Q1 2025 Earnings Report on May 15, 2025 and conduct investor webcast. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress Pharmaceuticals Gastrointestinal Distress Earnings Report Investor Webcast Jaguar Health
BRIEF published on 05/08/2025 at 15:35, 1 year 1 month ago Jaguar Health met en avant la sensibilisation au cancer des animaux de compagnie grâce à ses initiatives de soins contre le cancer Jaguar Health Chimiothérapie Cancer Des Animaux De Compagnie Canalevia ® -CA1 Sensibilisation Au Cancer
BRIEF published on 05/08/2025 at 15:35, 1 year 1 month ago Jaguar Health Highlights Pet Cancer Awareness with Its Cancer Care Initiatives Jaguar Health Chemotherapy Canalevia®-CA1 Pet Cancer Cancer Awareness
PRESS RELEASE published on 05/08/2025 at 15:30, 1 year 1 month ago Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs Jaguar Health, Inc. celebrates FDA conditional approval of Canalevia®-CA1 prescription drug for chemotherapy-induced diarrhea in dogs, highlighting National Pet Cancer Awareness Month and supportive cancer care initiatives FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea National Pet Cancer Awareness Month
BRIEF published on 05/07/2025 at 15:20, 1 year 1 month ago Jaguar Health met en avant les développements clés de Crofelemer en 2025 Crofelemer Approbation De La FDA Maladies Rares Thérapie Contre Le Cancer Catalyseurs 2025
BRIEF published on 05/07/2025 at 15:20, 1 year 1 month ago Jaguar Health Highlights Key 2025 Developments for Crofelemer Crofelemer FDA Approval Cancer Therapy Rare Diseases 2025 Catalysts
PRESS RELEASE published on 05/07/2025 at 15:15, 1 year 1 month ago Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts Jaguar Health's crofelemer, the only oral drug approved under FDA's Botanical Guidance, shows promising results in rare disease and cancer therapy-related diarrhea programs. Expected Q2-Q4 2025 catalysts discussed FDA Crofelemer Jaguar Health Catalysts Oral Drug
BRIEF published on 04/30/2025 at 14:20, 1 year 1 month ago Crofelemer montre des résultats prometteurs dans la réduction de la nutrition parentérale totale pour les maladies rares Crofelemer Syndrome De L'intestin Court Approbation Réglementaire Maladie D'inclusion Microvillositaire Réduction De La NPT
BRIEF published on 04/30/2025 at 14:20, 1 year 1 month ago Crofelemer Shows Promising Results in Reducing TPN for Rare Diseases Crofelemer Microvillus Inclusion Disease Short Bowel Syndrome Regulatory Approval TPN Reduction
PRESS RELEASE published on 04/30/2025 at 14:15, 1 year 1 month ago Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Jaguar Health's crofelemer shows promise in reducing TPN needs for MVID and SBS-IF patients. Investor webcast to review proof-of-concept study results presented at ELITE PED-GI Congress Crofelemer Investor Webcast Jaguar Health MVID SBS-IF
Published on 06/26/2026 at 23:00, 40 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 50 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 1 hour 25 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/26/2026 at 14:05, 9 hours 35 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 23:36, 4 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 4 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 12 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 19:50, 3 hours 50 minutes ago Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live